ライフサイエンスコーパス: adenosine deaminase

1 ding of a new series of potent inhibitors of Adenosine Deaminase.

2 12a and ent-14a were moderate substrates for adenosine deaminase.

3 (4)one, were screened against calf-intestine adenosine deaminase.

4 9a, 10a, and 11a are moderate substrates for adenosine deaminase.

5 ons were consistent with editing by host RNA adenosine deaminase.

6 alogues 11a and 12a were weak substrates for adenosine deaminase.

7 A by the enzyme double-stranded RNA-specific adenosine deaminase.

8 d from 2-amino-6-chloropurine riboside using adenosine deaminase.

9 n which 5'-methylthioinosine is generated by adenosine deaminase.

10 polyadenylation, and even RNA editing by an adenosine deaminase.

11 6a were moderately active as substrates for adenosine deaminase.

12 DO deaminase complexing protein 2 (CD26) and adenosine deaminase.

13 e by direct dehydroxylamination catalyzed by adenosine deaminase.

14 raded in the extracellular space by secreted adenosine deaminase.

15 e to inosine was completely inhibited by the adenosine deaminase 1 (ADA1) inhibitor erythro-9-(2-hydr

16 egulation of the editing enzyme RNA-specific adenosine deaminase 1 (ADAR1) was documented during acut

17 Reduction of adenosine deaminase 2 (ADA2) activity due to autosomal-r

18 me chromosome region, candidate 1), encoding adenosine deaminase 2 (ADA2), that were predicted to be

19 essive mutations in CECR1, the gene encoding adenosine deaminase 2 (ADA2).

20 Deficiency of adenosine deaminase 2 (DADA2) is caused by biallelic del

21 deaminase Arg and a predicted tRNA-specific adenosine deaminase 2 in A. thaliana.

22 rrel structure with structural similarity to adenosine deaminase, a relationship that is undetectable

23 inhibition characteristics of coformycins to adenosine deaminase, a series of analogues (1a-1h) conta

24 ded for antigen receptor development, one is adenosine deaminase--a purine salvage pathway enzyme, an

25 ated [Ca(2+)](i) responses were augmented by adenosine deaminase, A1, and A3R antagonists.

26 hydrolytic deamination process, catalyzed by adenosine deAminase acting on double-stranded RNA (ADAR)

27 zymes responsible for editing in mammals are adenosine deaminase acting on RNA (ADAR) 1 and 2.

28 ary structure and the temporal expression of adenosine deaminase acting on RNA (ADAR) contribute to c

29 may be generated by RNA editing mediated by adenosine deaminase acting on RNA (ADAR) enzymes that re

30 e reduced posttranscriptional RNA editing by adenosine deaminase acting on RNA (ADAR) enzymes, but th

31 >I RNA editing is mediated by adenosine deaminase acting on RNA (ADAR) enzymes.

32 t ADR-1, a deaminase-deficient member of the adenosine deaminase acting on RNA (ADAR) family, is comp

33 Yeasts and filamentous fungi do not have adenosine deaminase acting on RNA (ADAR) orthologs and a

34 R3 is a catalytically inactive member of the Adenosine Deaminase Acting on RNA (ADAR) protein family,

35 Other DRBPs such as Staufen, adenosine deaminase acting on RNA (ADAR), and spermatid

36 UNE2/PCA3 double-stranded RNA that undergoes adenosine deaminase acting on RNA (ADAR)-dependent adeno

37 nts, and apply it to a genome-scale study of adenosine deaminase acting on RNA (ADAR)-mediated RNA ed

38 s changed to inosine in RNA, is catalyzed by adenosine deaminase acting on RNA (ADAR).

39 bors the inflammation-responsive RNA editase adenosine deaminase acting on RNA (ADAR)1 gene, occurs i

40 The human RNA-editing enzyme adenosine deaminase acting on RNA (ADAR1) carries a uniq

41 Here, we report that adenosine deaminase acting on RNA (ADAR1), responsible f

42 consistent with conversions catalyzed by the adenosine deaminase acting on RNA (ADAR1).

43 e repair, we exploit the catalytic domain of Adenosine Deaminase Acting on RNA (ADAR2) that deaminate

44 Adenosine Deaminase Acting on RNA 1 (ADAR1) is an RNA-ed

45 We show here that RNA editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) is critical

46 rotein kinase regulated by RNA (PKR) and the adenosine deaminase acting on RNA 1 (ADAR1).

47 and the sensing of viral RNA is regulated by adenosine deaminase acting on RNA 1 (ADAR1).

48 AC)7 with the Zalpha-binding domain of human adenosine deaminase acting on RNA 1 (ADAR1, hZalphaADAR1

49 n directly inhibits editing, we do show that adenosine deaminase acting on RNA 1 and 2 and fibrillari

50 iated knockdown demonstrated that editing is adenosine deaminase acting on RNA 1 and 2 dependent.

51 Adenosine deaminase acting on RNA 2 (ADAR2) is a nuclear

52 , a dysfunctional form of the editing enzyme adenosine deaminase acting on RNA B1 was found more comm

53 sine-to-inosine deaminase activity by ADAR2 (adenosine deaminase acting on RNA type 2) to transcripts

54 ADAR1 (adenosine deaminase acting on RNA) catalyzes the convers

55 ADAR1 (adenosine deaminase acting on RNA) catalyzes the deamina

56 editing enzymes or of endogenous human ADAR (adenosine deaminase acting on RNA) enzymes.

57 ional modification of RNA, mediated by ADAR (adenosine deaminase acting on RNA) enzymes.

58 s report, we establish that Drosophila ADAR (adenosine deaminase acting on RNA) forms a dimer on doub

59 ADAR1 (adenosine deaminase acting on RNA) is widely expressed i

60 Adar (adenosine deaminase acting on RNA) mutant flies expressi

61 ADAR1, the interferon (IFN)-inducible adenosine deaminase acting on RNA, catalyzes the C-6 dea

62 ites were characteristic of those favored by adenosine deaminase acting on RNA-1 (ADAR1), which catal

63 s contain motifs favoring recognition by the adenosine deaminase acting on RNA-1 (ADAR1).

64 adenosine-to-inosine RNA editing mediated by adenosine deaminase acting on RNA1 (ADAR1) promotes canc

65 Adenosine deaminases acting on double-stranded RNA (ADAR

66 genous viral elements are silenced by ADARs [adenosine deaminases acting on double-stranded RNA (dsRN

67 o-inosine (A-to-I) RNA editing, catalyzed by Adenosine DeAminases acting on double-stranded RNA(dsRNA

68 RNA editing by adenosine deaminases acting on dsRNA (ADAR) has become o

69 editing is catalyzed by a family of enzymes, adenosine deaminases acting on dsRNA (ADARs).

70 enrichment with known features of targets of adenosine deaminases acting on RNA (ADAR) and validation

71 Adenosine deaminases acting on RNA (ADAR) convert adenos

72 vivo sequence-specific RNA base editing via adenosine deaminases acting on RNA (ADAR) enzymes with a

73 ate synthetases-like (OASL)(rs1169279CT) and adenosine deaminases acting on RNA (ADAR)(rs1127309TC) g

74 n double-stranded RNA (dsRNA) is mediated by adenosine deaminases acting on RNA (ADAR).

75 in double-stranded RNA through the action of adenosine deaminases acting on RNA (ADAR).

76 Adenosine deaminases acting on RNA (ADAR1 and ADAR2) are

77 Adenosine deaminases acting on RNA (ADARs) are best know

78 Adenosine deaminases acting on RNA (ADARs) are enzymes t

79 Adenosine deaminases acting on RNA (ADARs) are involved

80 Adenosine deaminases acting on RNA (ADARs) catalyze the

81 Adenosine deaminases acting on RNA (ADARs) catalyze the

82 Adenosine deaminases acting on RNA (ADARs) catalyze the

83 Adenosine deaminases acting on RNA (ADARs) catalyze the

84 The adenosine deaminases acting on RNA (ADARs) comprise a fa

85 Adenosine deaminases acting on RNA (ADARs) convert adeno

86 Adenosine deaminases acting on RNA (ADARs) convert adeno

87 Adenosine deaminases acting on RNA (ADARs) hydrolyticall

88 ation of particular adenosines to inosine by adenosine deaminases acting on RNA (ADARs).

89 adenosine-to-inosine (A-to-I) RNA editing by adenosine deaminases acting on RNA (ADARs).

90 sine to inosine, a reaction catalyzed by the adenosine deaminases acting on RNA (ADARs).

91 protein kinase R, oligoadenylate synthases, adenosine deaminases acting on RNA, RNA interference sys

92 Adenosine deaminases acting on RNAs (ADARs) convert aden

93 t anticodon position in tRNA is catalyzed by adenosine deaminases acting on tRNA (ADATs).

94 ar to the anticodon loop of tRNA targeted by adenosine deaminases acting on tRNA (ADATs).

95 Baseline 5-HT levels increased with adenosine deaminase, activation of A2Rs, and inhibition

96 Return of significant amount of tissue adenosine deaminase activity by 24 hrs and later recover

97 Adenosine deaminase activity was similar in serum of pat

98 th dramatic increases in CD26 expression and adenosine deaminase activity were observed in PTMs durin

99 undamental RNA modification, is regulated by adenosine deaminase (AD) domain containing proteins.

100 Little is known about the role of adenosine deaminase (ADA) 2 in regulation of immune resp

101 the source of the purine precursors, making adenosine deaminase (ADA) a key enzyme in the pathway of

102 adenosine receptor expression and decreased adenosine deaminase (ADA) activity in C57BL/6 animals.

103 3 overexpression on the levels of adenosine, adenosine deaminase (ADA) activity, and adenosine recept

104 functions that involve its interaction with adenosine deaminase (ADA) and other extracellular matrix

105 ere we apply gene array analysis identifying adenosine deaminase (ADA) as a key molecule that delinea

106 Genetic deficiency of adenosine deaminase (ADA) can cause profound lymphopenia

107 Adenosine deaminase (ADA) can localize to the cell surfa

108 version of AMP to adenosine, whereas soluble adenosine deaminase (ADA) catabolizes adenosine to inosi

109 Inherited defects in adenosine deaminase (ADA) cause a subtype of severe comb

110 Inherited defects in the function of adenosine deaminase (ADA) cause severe combined immunode

111 sed a retroviral vector containing the human adenosine deaminase (ADA) cDNA to transduce mature perip

112 Adenosine deaminase (ADA) deficiency causes severe cellu

113 Adenosine deaminase (ADA) deficiency is a rare, autosoma

114 Adenosine deaminase (ADA) deficiency is associated with

115 ly, we provide in vivo genetic evidence that adenosine deaminase (ADA) deficiency leads to excess pla

116 Adenosine deaminase (ADA) deficiency results in the accu

117 Adenosine deaminase (ADA) deficiency, a cause of X-linke

118 cy caused by gammac-deficiency (SCID X1) and adenosine deaminase (ADA) deficiency.

119 Adenosine deaminase (ADA) gene defects are among the mos

120 opment, with a Zap70 transgene driven by the adenosine deaminase (ADA) gene enhancer, which is active

121 identified near the second exon of the human adenosine deaminase (ADA) gene.

122 Mice deficient in the enzyme adenosine deaminase (ADA) have small lymphoid organs tha

123 IMER columns were prepared by entrapment of adenosine deaminase (ADA) into sol-gel derived monolithi

124 In mammalian intestine, adenosine deaminase (ADA) is expressed at high levels on

125 Adenosine deaminase (ADA) is expressed intracellularly b

126 Adenosine deaminase (ADA) is the principal catabolic enz

127 investigate the mechanism by which a lack of adenosine deaminase (ADA) leads to a failure of T cell p

128 Three days later, an adenosine deaminase (ADA) level of 118.1 U/L (normal ran

129 However, rapid degradation by adenosine deaminase (ADA) limits its overall therapeutic

130 Human adenosine deaminase (ADA) occurs as a 41-kDa soluble mon

131 The plasmodial enzyme adenosine deaminase (ADA) plays a central role in purine

132 Mutations in the gene encoding adenosine deaminase (ADA), a purine salvage enzyme, lead

133 In the absence of adenosine deaminase (ADA), adenosine and other purine me

134 Here we report that mice lacking adenosine deaminase (ADA), an enzyme necessary for the b

135 of adenosine, resulting from a deficiency in adenosine deaminase (ADA), developed renal dysfunction a

136 Adenosine deaminase (ADA), IRISA-TB (interferon gamma ul

137 ond T cell costimulatory receptor component, adenosine deaminase (ADA), on the process of replicative

138 4(+)CD25(high) T cells express low levels of adenosine deaminase (ADA), the enzyme responsible for ad

139 is not a substrate for ADAR, in contrast to adenosine deaminase (ADA), which catalyzes a similar rea

140 n two independent animal models of priapism, adenosine deaminase (ADA)-deficient mice and SCD transge

141 Adenosine deaminase (ADA)-deficient mice develop progres

142 The current study utilized adenosine deaminase (ADA)-deficient mice to determine wh

143 To accomplish this, adenosine deaminase (ADA)-deficient mice were treated wi

144 dependent pulmonary inflammation observed in adenosine deaminase (ADA)-deficient mice.

145 two independent priapic models: SCD mice and adenosine deaminase (ADA)-deficient mice.

146 topoietic stem cell transplantation (HCT) of adenosine deaminase (ADA)-deficient severe combined immu

147 ted a gene therapy trial in 10 patients with adenosine deaminase (ADA)-deficient severe combined immu

148 Adenosine deaminase (ADA)-deficient severe combined immu

149 Adenosine deaminase (ADA)-severe combined immunodeficien

150 iscovery of a selective covalent modifier of adenosine deaminase (ADA).

151 vo because of rapid metabolic degradation by adenosine deaminase (ADA).

152 dAdo is maintained at low levels by adenosine deaminase (ADA).

153 ation by the Zn(2+)-dependent protein enzyme adenosine deaminase (ADA).

154 Adenosine deaminase (ADA, EC 3.5.4.4) is a ubiquitous (b

155 of adenosines to inosines by dsRNA-specific adenosine deaminase (ADAR) can lead to the nuclear reten

156 ta domain from the human double-stranded RNA adenosine deaminase ADAR1 at 0.97 A, determined by singl

157 tigenome at the amber/W site by the host RNA adenosine deaminase ADAR1 is a critical step in the HDV

158 a preferred editing site for the RNA editing adenosine deaminase ADAR1.

159 T2CR editing is caused by down-regulation of adenosine deaminase ADAR2 and that editing of at least o

160 multiple MS2 binding sites that recruit the adenosine deaminase ADAR2 fused to an MS2 capsid protein

161 nuclear enzyme responsible for Q/R-editing, adenosine deaminase (ADAR2), is increased during differe

162 The RNA-editing adenosine deaminases (ADARs) catalyze deamination of ade

163 tent with RNA editing by one of the host RNA adenosine deaminases (ADARs).

164 Adenosine deaminases (ADAs) from human, bovine, and Plas

165 Recombinant ADGF-A and ADGF-D are active adenosine deaminases (ADAs), and they cause polarization

166 mutant analysis; however, the gene encoding adenosine deaminase (ADD) in H. pylori remained unidenti

167 Mononuclear cell adenosine deaminase after PT was inhibited 84%.

168 -dependently attenuated the activity of both adenosine deaminase and adenosine kinase (both p </= .00

169 Furthermore, both adenosine deaminase and adenosine kinase activity was si

170 CMSD is very similar to that of Zn-dependent adenosine deaminase and Fe-dependent cytosine deaminase,

171 Adenosine deaminase and IRISA-TB sensitivity were 84.4%

172 armacophore leads to increased resistance to adenosine deaminase and purine nucleoside phosphorylase

173 o be susceptible to enzymatic conversions by adenosine deaminase and purine nucleoside phosphorylase,

174 identified by mass spectrometry include RNA adenosine deaminases and several novel factors.

175 mbination of inhibitors of adenosine kinase, adenosine deaminase, and the equilibrative nucleoside tr

176 phosphatases (inactive), CD-39-type apyrase, adenosine deaminases, and esterases.

177 smodium purine nucleoside phosphorylases and adenosine deaminases are inhibited.

178 oflavin biosynthesis, the chloroplastic tRNA adenosine deaminase Arg and a predicted tRNA-specific ad

179 oxycoformycin (pentostatin), an inhibitor of adenosine deaminase, as a postinsult, or prophylactic tr

180 Adenosine deaminase associated with RNA1 (ADAR1) deregul

181 tes from purine nucleoside phosphorylase and adenosine deaminase blockade but not when erythrocyte ad

182 rowth factor that is the major extracellular adenosine deaminase, can cause polyarteritis nodosa vasc

183 ogs of yeast (Saccharomyces cerevisiae) tRNA adenosine deaminases catalyze adenosine-to-inosine editi

184 The essential tRNA-specific adenosine deaminase catalyzes the deamination of adenosi

185 ucturally related N-nucleoside inhibitors of adenosine deaminase characterized by an unusual 1,3-diaz

186 holinesterase; dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing protein 2); glucokinase (

187 the mechanism of APC variation, we measured adenosine deaminase concentration, adenosine uptake by r

188 Bypassing metabolically the adenosine deaminase defect by inosine supplementation wa

189 severe combined immune deficiency caused by adenosine deaminase defects (ADA-SCID).

190 monary disease, asthma, cystic fibrosis, and adenosine deaminase deficiency (ADA(-/-)).

191 Adenosine deaminase deficiency is a disorder of purine m

192 Adenosine deaminase deficiency results in toxic accumula

193 inase 3 forms of SCID and greatly reduced in adenosine deaminase deficiency SCID but often present in

194 eletion recombinant excision circles and for adenosine deaminase deficiency using tandem mass spectro

195 complex inheritance; these diseases include adenosine deaminase deficiency-related severe combined i

196 Investigations of patients with adenosine deaminase deficient severe combined immunodefi

197 del of adenosine-mediated lung injury is the adenosine deaminase-deficient (Ada(-/-)) mouse.

198 Adenosine deaminase-deficient (ADA-deficient) mice devel

199 he pulmonary inflammation and injury seen in adenosine deaminase-deficient (ADA-deficient) mice, whic

200 eic HSCT that has shown clinical benefit for adenosine deaminase-deficient (ADA-deficient) SCID when

201 ovides another treatment of the X-linked and adenosine deaminase-deficient forms of SCID, and we disc

202 py for severe combined immune deficiency-X1, adenosine deaminase-deficient forms of severe combined i

203 ue of the JCI, Sun et al. report findings in adenosine deaminase-deficient mice that suggest the occu

204 as BM from children on enzyme treatment for adenosine deaminase-deficient SCID (n = 2).

205 Gene therapy (GT) for adenosine deaminase-deficient severe combined immune def

206 A patient with adenosine deaminase-deficient severe combined immune def

207 dence of this DFSP in children affected with adenosine deaminase-deficient severe combined immunodefi

208 the underlying genetic defect, diagnosis of adenosine deaminase-deficient severe combined immunodefi

209 In dramatic contrast, 39 adenosine deaminase-deficient severe combined immunodefi

210 -inducible double-stranded (ds) RNA-specific adenosine deaminase, downregulates host innate responses

211 al to Saccharomyces cerevisiae AAH and human adenosine deaminase enzymes, respectively, catalyzes ade

212 Adenine base editors comprise an adenosine deaminase, evolved in vitro, and a Cas9 nickas

213 riations in each of three genes (An. gambiae adenosine deaminase, fibrinogen-related protein 30, and

214 ed and screened in vitro against a mammalian adenosine deaminase for inhibitory activity.

215 transition states described recently for the adenosine deaminases from human, bovine, and Plasmodium

216 ox deficient G+C-rich promoter of the murine adenosine deaminase gene (Ada) requires a 48-bp minimal

217 rogenitors also require a signal mediated by Adenosine deaminase growth factor A (Adgf-A) arising fro

218 e, HRP-avidin was substituted with the human adenosine deaminase (hADA1)-streptavidin complex and ade

219 Pentostatin, a potent inhibitor of adenosine deaminase, has activity in acute GVHD.

220 Human adenosine deaminase (HsADA) is present in most mammalian

221 al TMN at four different times using Fos and adenosine deaminase immunohistochemistry and recordings

222 s showed pentostatin significantly inhibited adenosine deaminase in canine lymphocytes.

223 icity, which could be mimicked by inhibiting adenosine deaminase in control lines.

224 and NBTI and were significantly inhibited by adenosine deaminase, indicating a role for extracellular

225 Pentostatin, a potent inhibitor of adenosine deaminase, induces lymphocyte apoptosis and ma

226 Furthermore, adenosine deaminase inhibition in control induced astroc

227 ytho-9-(2-hydroxy-3-nonyl)adenine (EHNA), an adenosine deaminase inhibitor, for 48 hours increased GP

228 Pentostatin, an adenosine deaminase inhibitor, leads to lymphocyte deple

229 2'-deoxycoformycin (DCF), a potent adenosine deaminase inhibitor, reversed the inhibitory e

230 ADAR2 is a double-stranded RNA-specific adenosine deaminase involved in the editing of mammalian

231 ADAR2 is a double-stranded RNA-specific adenosine deaminase involved in the editing of mammalian

232 ADAR2 is a double-stranded-RNA-specific adenosine deaminase involved in the editing of mammalian

233 d is phylogenetically related to a family of adenosine deaminases involved in RNA editing.

234 Furthermore, studies using adenosine deaminase knockout mice suggested that elevate

235 Deficiency of the purine salvage enzyme adenosine deaminase leads to SCID (ADA-SCID).

236 We propose that MTH1 acts in concert with adenosine deaminase-like protein isoform 1 (ADAL1) to pr

237 ence analyses indicated that the protein was adenosine deaminase-like protein isoform 1 (ADAL1).

238 oteins (AtTAD2 and AtTAD3, for tRNA-specific adenosine deaminase) localize to the nucleus and interac

239 We have shown that the mouse adenosine deaminase (MADA) gene locus is packaged into a

240 Murine adenosine deaminase (mADA) is a 40 kDa (beta/alpha)(8)-b

241 spread TIM barrel proteins, targeting murine adenosine deaminase (mADA) that catalyzes the irreversib

242 combination with modulation of the level of adenosine deaminase may represent a beneficial therapeut

243 enger RNA was upregulated (p = .01), whereas adenosine deaminase messenger RNA was downregulated (p =

244 tion (CD39 and CD73) and breakdown (CD26 and adenosine deaminase) on T cells from blood, lymph nodes,

245 , treatment of wild-type mice with pegylated adenosine deaminase or CD73 antibodies also significantl

246 d the respiratory burst, and, in cocultures, adenosine deaminase overcame the inhibitory effects of e

247 t activity of another purine salvage enzyme, adenosine deaminase (PfADA), was normal.

248 However adenosine deaminase played a minor role in determining t

249 upon binding to the Zalpha domain of the RNA adenosine deaminase protein.

250 its prokaryotic orthologs additionally have adenosine deaminase, purine nucleoside phosphorylase, an

251 Interestingly, down-regulation of adenosine deaminase-related growth factor A (Adgf-A) fro

252 Drosophila PDGF/VEGF receptor), STAT92E, and adenosine deaminase-related growth factor A (ADGF-A).

253 a genetic analysis of a novel family of six adenosine deaminase-related growth factors (ADGFs).

254 RNA (ADAR1 and ADAR2) are human RNA-editing adenosine deaminases responsible for the conversion of a

255 e double-stranded RNA (dsRNA) editing enzyme adenosine deaminase RNA specific (ADAR), the RNase DICER

256 portant role for biased hypermutation via an adenosine deaminase, RNA-specific (ADAR)-like activity.

257 cancer transcriptomes demonstrate that ADAR (adenosine deaminase, RNA-specific)-mediated RNA editing

258 xenograft model used is not informative for adenosine deaminase-SCID, whereas hypomorphic mutations

259 mproved outcomes for 'difficult' conditions [adenosine deaminase-severe combined immunodeficiency (AD

260 entiation-associated) and lysosome function (adenosine deaminase) showed differential alternative spl

261 clic AMP production was reduced by exogenous adenosine deaminase, suggesting that A(2b) receptors sen

262 n-5-ylamino]ethyl)phe nol (ZM241385) but not adenosine deaminase, suggesting that constitutive activa

263 Bacterial tRNA-specific adenosine deaminase (TadA) catalyzes the essential deami

264 gh a new pathway involving RNA editing by an adenosine deaminase that acts on double-stranded RNA (AD

265 eporter sensitive to Drosophila melanogaster adenosine deaminase that acts on RNA (dADAR) activity an

266 the endogenous targeting domains from human adenosine deaminase that acts on RNA 2 and replacing the

267 In this study, we identify adenosine deaminase that acts on RNA 3 (ADAR3) as an imp

268 ADAR (adenosine deaminase that acts on RNA) editing enzymes ta

269 In this work, we show that ADAR2 (adenosine deaminase that acts on RNA), an RNA editing en

270 The ADAR1 gene encodes an RNA-specific adenosine deaminase that alters the functional activity

271 ADAR1 is an RNA-specific adenosine deaminase that edits RNA sequences.

272 ne-to-inosine (A-to-I) editing, generated by adenosine deaminases that act on double-stranded RNA (AD

273 Hyperediting by adenosine deaminases that act on RNA (ADAR) enzymes was

274 Adenosine Deaminases that act on RNA (ADARs) are enzymes

275 Adenosine deaminases that act on RNA (ADARs) are RNA edi

276 Adenosine deaminases that act on RNA (ADARs) carry out a

277 The adenosine deaminases that act on RNA (ADARs) catalyze th

278 An enzyme family known as adenosine deaminases that act on RNA (ADARs) catalyzes a

279 Adenosine deaminases that act on RNA (ADARs) constitute

280 Adenosine deaminases that act on RNA (ADARs) deaminate a

281 Although there are no reports that adenosine deaminases that act on RNA (ADARs) require a c

282 le-stranded RNA may undergo hyper-editing by adenosine deaminases that act on RNA (ADARs), where up t

283 rgo extensive modification (hyperediting) by adenosine deaminases that act on RNA (ADARs), where up t

284 rgo covalent modification (hyper-editing) by adenosine deaminases that act on RNA (ADARs), whereby up

285 one or more of the cellular enzymes known as adenosine deaminases that act on RNA (ADARs).

286 ADARs are adenosine deaminases that act on RNA and are responsible

287 Adenosine deaminases that act on RNA are a conserved fam

288 In mammals, it is mediated by a family of adenosine deaminases that act on RNAs (ADARs).

289 the crystal structure are conserved in some adenosine deaminases that act on transfer RNA (tRNA) (AD

290 ADAR1 isoforms are adenosine deaminases that edit and destabilize double-st

291 " behavior, as illustrated by the ability of adenosine deaminase to deaminate (tz)A as effectively as

292 We evolved a transfer RNA adenosine deaminase to operate on DNA when fused to a ca

293 Treatment with pegylated adenosine-deaminase to enhance extracellular adenosine b

294 we further evolve ABE7.10 using a library of adenosine deaminase variants to create ABE8s.

295 with extracellular ATP scavengers [apyrase + adenosine deaminase] versus 95 +/- 12% surviving cells w

296 Breakdown of adenosine by adenosine deaminase was the major source of the inosine/

297 was also observed in mice lacking the enzyme adenosine deaminase, which degrades adenosine.

298 effects of NBMPR were partially reversed by adenosine deaminase, which facilitates the metabolic deg

299 ne deamination defect caused by reduction of adenosine deaminase, which is also observed in induced a

300 t Hp0267 represents a second enzyme class of adenosine deaminase whose phyletic distribution among pr